| Full Name | Luke Hobbs |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist - Mental Health |
| Location | 1432 Ingra St, Anchorage, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538720800 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XM0800X | Occupational Therapist - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Luke Hobbs, 1432 Ingra St, Anchorage, AK 99501-5434 Ph: () - | Luke Hobbs, 1432 Ingra St, Anchorage, AK 99501-5434 Ph: (907) 261-5343 |
News Archive
A new study from the University of Maryland found that use of antipsychotic drugs from 1997 to 2006 increased 7- to 12-fold in a Medicaid population of about 500,000 children ages two to 17.
The group led by Dr. Enrique J. Calderón - "Clinical Epidemiology and Vascular Risk" at the Institute of Biomedicine of Seville - IBiS/University Hospitals Virgen del Rocío and Macarena/CSIC/University of Seville, also a member of CIBERESP, participated in a project with researchers from CIBER-BBN, in which they developed systems to detect Pneumocystis jirovecii, an atypical fungus responsible for very severe pneumonia in immunosuppressed patients.
HealthSouth Corporation (NYSE: HLS) today announced that the Company entered into separate, privately negotiated exchange agreements under which it will issue $320 million in aggregate principal amount of new 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's outstanding 6.5% Series A Convertible Perpetual Preferred Stock, par value $0.10 per share.
Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.
Ontarians will enjoy better access to eye health care now that optometrists can prescribe medications for sight-threatening conditions like eye infections and glaucoma.
› Verified 1 days ago
Paige N Thorne, MOTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3831 Piper St Ste 220, Anchorage, AK 99508 Phone: 760-936-9766 | |
Forget Me Not Ot Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1048 W International Airport Rd, Suite 103, Anchorage, AK 99518 Phone: 907-317-5545 Fax: 907-865-2499 | |
Eva Cress Lyons, OTD Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 3801 Lake Otis Pkwy, Anchorage, AK 99508 Phone: 907-562-2277 | |
Mrs. Stacey Marie Lord, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Ms. Tamara Dawn Moore, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 W 41st Ave Ste 103, Anchorage, AK 99503 Phone: 907-306-1728 Fax: 907-334-9320 | |
Marie Koleka Swanson, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Alexa Hanley, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 9100 Centennial Cir, Anchorage, AK 99504 Phone: 907-333-8100 |